Sung Jun Ma1, Lucas M Serra2, Austin J Bartl2, Hye Ri Han2, Fatemeh Fekrmandi1, Austin J Iovoli1, Gregory M Hermann1, Han Yu3, Anurag K Singh1. 1. Department of Radiation Medicine, Roswell Park Comprehensive Cancer Center, 665 Elm Street, Buffalo, NY 14203. USA. 2. Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, 955 Main Street, Buffalo, NY 14203. USA. 3. Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, 665 Elm Street, Buffalo, NY 14203. USA.
Abstract
Background: Neoadjuvant therapy (NT), either with systemic treatment alone or in combination with radiation, is often utilized in the management of pancreatic adenocarcinoma to increase the likelihood of margin-negative resection. Following NT and resection, additional adjuvant chemotherapy (AC) can be considered for select patients and has been shown to improve overall survival (OS). This National Cancer Data Base (NCDB) analysis was performed to evaluate the outcomes of AC versus observation for resected pancreatic adenocarcinoma treated with NT. Methods: The NCDB was queried for primary stage I-II cT1-3N0-1M0 resected pancreatic adenocarcinoma treated with NT (2004-2015). Baseline patient, tumor, and treatment characteristics were extracted. The primary endpoint was OS. With a 6-month conditional landmark, Kaplan-Meier analysis, multivariable Cox proportional hazards method, 1:1 propensity score matching were used to analyze the data. Results: A total of 1737 eligible patients were identified, of which 1247 underwent postoperative observation compared to 490 with AC. The overall median follow-up was 34.7 months. The addition of AC showed improved survival on the multivariate analysis (HR 0.78, p<0.001). Of 490 propensity-matched pairs, all variables were well balanced, including age (p=0.61), Charlson-Deyo comorbidity score (p=0.80), ypT stage (p=0.93), ypN stage (p=0.83), surgical margin (p=0.83), duration of postoperative inpatient admission (p=0.96), and 30-day unplanned readmission after resection (p=0.34). AC remained statistically significant for improved OS, with median OS of 26.3 months vs 22.3 months and 2-year OS of 63.9% vs 52.9% for the observation cohort (p<0.001). Treatment interaction analysis showed OS benefit of AC for patients with smaller tumors (HR 0.67, p<0.001 for <3.1 cm vs HR 0.93, p=0.48 for ≥3.1 cm). Conclusion: Using propensity score matched analysis, our findings suggest a survival benefit for adjuvant chemotherapy compared to observation following NT and surgery for resectable pancreatic adenocarcinoma, especially in patients with smaller tumors. Prospective studies are needed to identify subset of patients that would benefit from adjuvant chemotherapy.
Background: Neoadjuvant therapy (NT), either with systemic treatment alone or in combination with radiation, is often utilized in the management of pancreatic adenocarcinoma to increase the likelihood of margin-negative resection. Following NT and resection, additional adjuvant chemotherapy (AC) can be considered for select patients and has been shown to improve overall survival (OS). This National Cancer Data Base (NCDB) analysis was performed to evaluate the outcomes of AC versus observation for resected pancreatic adenocarcinoma treated with NT. Methods: The NCDB was queried for primary stage I-II cT1-3N0-1M0 resected pancreatic adenocarcinoma treated with NT (2004-2015). Baseline patient, tumor, and treatment characteristics were extracted. The primary endpoint was OS. With a 6-month conditional landmark, Kaplan-Meier analysis, multivariable Cox proportional hazards method, 1:1 propensity score matching were used to analyze the data. Results: A total of 1737 eligible patients were identified, of which 1247 underwent postoperative observation compared to 490 with AC. The overall median follow-up was 34.7 months. The addition of AC showed improved survival on the multivariate analysis (HR 0.78, p<0.001). Of 490 propensity-matched pairs, all variables were well balanced, including age (p=0.61), Charlson-Deyo comorbidity score (p=0.80), ypT stage (p=0.93), ypN stage (p=0.83), surgical margin (p=0.83), duration of postoperative inpatient admission (p=0.96), and 30-day unplanned readmission after resection (p=0.34). AC remained statistically significant for improved OS, with median OS of 26.3 months vs 22.3 months and 2-year OS of 63.9% vs 52.9% for the observation cohort (p<0.001). Treatment interaction analysis showed OS benefit of AC for patients with smaller tumors (HR 0.67, p<0.001 for <3.1 cm vs HR 0.93, p=0.48 for ≥3.1 cm). Conclusion: Using propensity score matched analysis, our findings suggest a survival benefit for adjuvant chemotherapy compared to observation following NT and surgery for resectable pancreatic adenocarcinoma, especially in patients with smaller tumors. Prospective studies are needed to identify subset of patients that would benefit from adjuvant chemotherapy.
Authors: Neil David Saunders; Shawnn D Nichols; Michael Alfredo Antiporda; Kristen Johnson; Kerri Walker; Rhonda Nilsson; Lisa Graham; Matt Old; Rebecca B Klisovic; Sam Penza; Carl R Schmidt Journal: J Oncol Pract Date: 2015-01-13 Impact factor: 3.840
Authors: Eva Versteijne; Mustafa Suker; Karin Groothuis; Janine M Akkermans-Vogelaar; Marc G Besselink; Bert A Bonsing; Jeroen Buijsen; Olivier R Busch; Geert-Jan M Creemers; Ronald M van Dam; Ferry A L M Eskens; Sebastiaan Festen; Jan Willem B de Groot; Bas Groot Koerkamp; Ignace H de Hingh; Marjolein Y V Homs; Jeanin E van Hooft; Emile D Kerver; Saskia A C Luelmo; Karen J Neelis; Joost Nuyttens; Gabriel M R M Paardekooper; Gijs A Patijn; Maurice J C van der Sangen; Judith de Vos-Geelen; Johanna W Wilmink; Aeilko H Zwinderman; Cornelis J Punt; Casper H van Eijck; Geertjan van Tienhoven Journal: J Clin Oncol Date: 2020-02-27 Impact factor: 44.544
Authors: Susanna W L de Geus; Gyulnara G Kasumova; Mariam F Eskander; Sing Chau Ng; Tara S Kent; A James Moser; Alexander L Vahrmeijer; Mark P Callery; Jennifer F Tseng Journal: J Gastrointest Surg Date: 2017-10-04 Impact factor: 3.452
Authors: Jim Zhong; Kirtesh Patel; Jeffrey Switchenko; Richard J Cassidy; William A Hall; Theresa Gillespie; Pretesh R Patel; David Kooby; Jerome Landry Journal: Cancer Date: 2017-05-10 Impact factor: 6.860
Authors: Christina L Roland; Matthew H G Katz; Ching-Wei D Tzeng; Heather Lin; Gauri R Varadhachary; Rachna Shroff; Milind Javle; David Fogelman; Robert A Wolff; Jean N Vauthey; Christopher H Crane; Jeffrey E Lee; Jason B Fleming Journal: Ann Surg Oncol Date: 2015-09-08 Impact factor: 5.344
Authors: John P Neoptolemos; Daniel H Palmer; Paula Ghaneh; Eftychia E Psarelli; Juan W Valle; Christopher M Halloran; Olusola Faluyi; Derek A O'Reilly; David Cunningham; Jonathan Wadsley; Suzanne Darby; Tim Meyer; Roopinder Gillmore; Alan Anthoney; Pehr Lind; Bengt Glimelius; Stephen Falk; Jakob R Izbicki; Gary William Middleton; Sebastian Cummins; Paul J Ross; Harpreet Wasan; Alec McDonald; Tom Crosby; Yuk Ting Ma; Kinnari Patel; David Sherriff; Rubin Soomal; David Borg; Sharmila Sothi; Pascal Hammel; Thilo Hackert; Richard Jackson; Markus W Büchler Journal: Lancet Date: 2017-01-25 Impact factor: 79.321
Authors: Ryan P Merkow; Karl Y Bilimoria; James S Tomlinson; Jennifer L Paruch; Jason B Fleming; Mark S Talamonti; Clifford Y Ko; David J Bentrem Journal: Ann Surg Date: 2014-08 Impact factor: 12.969
Authors: Syed A Ahmad; Mai Duong; Davendra P S Sohal; Namita S Gandhi; Muhammad Shaalan Beg; Andrea Wang-Gillam; James L Wade; Elena Gabriela Chiorean; Katherine A Guthrie; Andrew M Lowy; Philip A Philip; Howard S Hochster Journal: Ann Surg Date: 2020-09-01 Impact factor: 13.787